Roche Unveils Game‑Changing Treatments Across Eye, Heart, Metabolism and Cancer at China Expo

Roche used its debut at the China International Import Expo to showcase a sweeping lineup of new medicines that could reshape care for dozens of diseases. In eye health, the company introduced Vamikibart, a monoclonal antibody injected directly into the eye that blocks a key inflammation driver, IL‑6. Phase‑III trials showed clearer vision and thinner retinal swelling in patients with uveitis, with Chinese participants enrolled alongside the global study. The firm also rolled out a suite of metabolic and cardiovascular candidates: an oral‑to‑injectable obesity pipeline, a twice‑yearly RNA‑interference shot called Zilebesiran that could simplify hypertension treatment, and pegozafermin, a first‑in‑class drug aimed at fatty‑liver disease (MASH). A standout eye‑device, the Port Delivery System (PDS), is a rice‑grain‑sized implant that slowly releases the anti‑VEGF drug ranibizumab for up to six months, cutting the need for frequent injections. In cancer, Roche highlighted Giredestrant, an oral therapy that outperformed standard hormone treatment in advanced breast cancer, and Cevostamab, a bispecific antibody that redirects T‑cells to attack resistant multiple‑myeloma cells. The pipeline also includes NXT007 for hemophilia A, Trontinemab—a brain‑penetrating antibody showing promise in Alzheimer’s trials, and prasinezumab, which added benefit for early Parkinson’s patients. Together, these announcements underline Roche’s ambition to cover the full treatment chain from discovery to delivery, with a new production base in China marking the next chapter of its century‑long commitment.

Read more

Big‑Pharma Goes All‑In on China: New R&D Hubs, Factories, and $5 Billion in Investments

At the 10th China Medical Innovation and Investment Conference, industry leaders highlighted how China has become a powerhouse for new drug discovery. More than half of the INDs approved by the U.S. FDA in 2024 now originate from Chinese research, a trend that multinational drug makers can’t ignore. In response, giants such as Eli Lilly, Pfizer, Bayer, AstraZeneca and Medtronic announced fresh R&D centers and production facilities across the country. AstraZeneca is fast‑tracking a $2.5 billion investment to launch its sixth global R&D hub in Beijing, while Medtronic opened its first digital‑health innovation base in Shanghai. Boehringer Ingelheim and Eli Lilly are also pouring billions into local manufacturing and capacity upgrades for diabetes and obesity treatments. Beyond building labs, multinationals are snapping up Chinese drug assets at a record pace, with companies like Takeda and Pfizer leading high‑value acquisitions. The shift is clear: China is no longer just a market for selling finished products; it is now a critical source of early‑stage innovation, from discovery through to production. Public data backs this surge—China now accounts for 38% of the world’s first‑in‑class drug launches and hosts nearly 2,000 clinical trials a year, a five‑fold increase since 2015. The result is a more competitive, higher‑quality landscape where the best global talent and technology converge on Chinese soil.

Read more

David Medical’s Subsidiary Wins Official Clearance for Cutting‑Edge Smart Device

David Medical announced that its wholly‑owned subsidiary has received a formal medical‑device registration certificate for its latest product, marking a major milestone for the company and underscoring the rapid shift toward digital, intelligent, and precision‑focused health technologies. The newly approved device was one of the headline attractions at this year’s China International Import Expo (CIIE), where it joined a lineup that included an “intelligent eyeglass” capable of picking up sound cues and a next‑generation MRI scanner being tested in clinical trials for Elon Musk’s brain‑computer‑interface venture. The launch comes at a time when China’s aging population is driving unprecedented demand for advanced medical equipment, raising the bar for manufacturers who must now compete on both innovation and quality. Over the past decade, many multinational medical firms that once simply imported technology have evolved into key partners in China’s burgeoning health‑tech ecosystem, establishing world‑class R&D hubs that accelerate the country’s output of groundbreaking medical solutions. Yet challenges remain. Domestic contract‑development‑manufacturing organizations (CDMOs) face a “precision craftsmanship” dilemma: despite a trillion‑yuan market opportunity, few have achieved the scale and reputation of giants like WuXi AppTec. Meanwhile, AI‑driven therapies are gaining traction, promising new ways to treat diseases by targeting the heart of the problem. David Medical’s certification win signals that the industry is moving forward, blending cutting‑edge tech with the urgent needs of an aging society.

Read more